PT  - JOURNAL ARTICLE
AU  - Owen W. J. Prall
AU  - Ravikiran Vedururu
AU  - Peter Lau
AU  - Andrew Fellowes
TI  - Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies
AID  - 10.1101/2020.11.11.20226845
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.11.20226845
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.11.20226845.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.11.20226845.full
AB  - Background Distinguishing metastases from new primary malignancies or vice versa is important because misclassification can result in inappropriate management. However, for some cases this distinction can be challenging, particularly for squamous cell carcinomas in which the usual surgical pathology approach, predominantly morphology and immunohistochemistry, are frequently non-contributory. We analysed tumor-associated mutations in order to determine whether they could help with this diagnostic dilemma.Methods Mutations in specific genes were identified with cBioPortal, a large publically available tumor sequence data set. Genes were selected based upon either their high overall prevalence of mutation, or their inclusion in an in-house tumor sequencing set. Tumor types analysed included various common adenocarcinomas, squamous cell carcinomas from multiple sites, urothelial carcinoma and melanoma. Individual mutations and sets of mutations within gene cohorts were compared by their diversity (or heterogeneity) index, prevalence and cumulative prevalence. We demonstrated the utility of this method by performing in-house sequencing of candidate genes in tumors from three patients for which morphology and immunohistochemistry were unable to distinguish between a metastasis and a new primary malignancy.Results Sequence data from relatively small cohorts of candidate genes readily identified highly diverse, low prevalence mutation profiles in most common malignancies including squamous cell carcinomas. The diversity index predicted the likelihood of an identical mutation profile occurring in an unrelated tumor. High yield gene cohorts could be predicted based on the primary tumor type. Most cohorts included TP53 due to both its high mutation prevalence and high mutation index of diversity. Identical, low prevalence mutations in multiple tumors from patients in the three case studies provided strong diagnostic certainty for metastases rather than new primary malignancies.Conclusions Most common tumors, including squamous cell carcinomas, have a readily identifiable mutation profiles that occur at a sufficiently low prevalence to effectively barcode or fingerprint the tumor. An identical mutation profile in a primary tumor and a new lesion provides strong evidence for a metastasis and effectively excludes a new primary malignancy, providing diagnostic confidence and aiding clinical management certainty.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was required.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peter MacCallum Cancer Centre Ethics Committee (approved; project ID #03/90)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is either publicly available in cBioportal.com or where generated on the 3 case studies is available on request as redacted files. https://www.cbioportal.org/ FFPEformalin-fixed paraffin-embeddedFDG-PETfluorodeoxyglucose-positron emission tomographyCTcomputed-tomographyPTCpapillary thyroid carcinomaSCCsquamous cell carcinoma